ROCKVILLE, Md. — BrainScope, a leading neurotechnology company advancing brain health diagnostics through computational neuroscience, announced the appointment of Matt Adams as its new Chief Executive Officer. Adams succeeds Laurie Silver, who will transition to the role of President while continuing to guide the company’s strategic direction and growth. Both Adams and Silver will serve on BrainScope’s Board of Directors.
Adams brings more than two decades of leadership experience in the MedTech sector, having guided companies through rapid innovation, expansion, and multiple successful exits. Over his career, he has delivered more than $1.3 billion in realized shareholder value, combining technical expertise with strategic vision across diagnostics, devices, and therapeutics. His background includes building AI-enabled platforms, developing neuro-focused diagnostic and interventional technologies, scaling global portfolios, and leading high-performing teams through fundraising and major transactions.
Silver, who became CEO two years ago, led BrainScope through a transformative period focused on operational efficiency, sustained revenue growth, and platform development. Under her leadership, the company achieved a 50 percent year-over-year increase in brain injury assessment revenue and built a multimodal deep learning foundation model with broad applications across central nervous system (CNS) disorders.
“Laurie has done a superb job of operating BrainScope for the last two years by putting the company on firm financial footing and transitioning the computational backbone into an innovative platform,” said Ralph Terkowitz, Chairman of the Board at BrainScope. “With the foundation now firmly in place, BrainScope is poised for transformational growth. Matt’s ability to lead high-performing teams, drive clinical and commercial innovation, and scale businesses globally makes him exactly the right person for BrainScope at this stage. The future is bright, and the Board couldn’t be more thrilled to have Matt and Laurie working together to bring our groundbreaking technology to more patients, providers, and health systems around the world.”
BrainScope made history as the first medical device in neurology to receive FDA clearance using a machine learning approach. The company’s recently developed deep learning platform expands its capacity to create novel biomarkers for diagnosing, predicting, and monitoring a wide range of brain-related conditions, including neurodegenerative diseases, stroke, and CNS disorder subtypes.
“I’m honored to join BrainScope at such a pivotal moment in its journey,” said Adams. “The company has built a rare combination of deep science and practical utility — technology that not only advances understanding, but drives meaningful change in care delivery. I look forward to building on that foundation to expand our innovation pipeline, broaden our global footprint, and extend BrainScope’s reach across the many areas of brain health where better answers are urgently needed.”
